Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030552 (paresis)
 5,831 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 7 year old boy presented with a history of recurrent episodes of sinusitis and otitis. He developed paresis of the external muscle of his right eye with exophthalmos. A biopsy of his sinus mucosa demonstrated necrotizing granulomatous involvement of the membranes with the presence of multiple giant cells interspersed in zones of fibrosis. A diagnosis of Wegener's granulomatosis was entertained. However the absence of pulmonary and renal manifestations did not allow for a definitive diagnosis to be made. He later developed hematuria and a renal biopsy demonstrated a renal lesions consistent with Wegener's granulomatosis. He has responded well to Cyclophosphamide and Prednisone therapy.
 ...
PMID:Wegener's granulomatosis in a 7 year old child. 653 Mar 40

Findings of electronystagmography in 30 patients with posterior cranial fossa tumor were analysed. Of the 23 cases of CPA tumor, size varied between 0.7-5.0 cm, the ENG showed: (1) The nystagmus occurred in 83% of patients. (2) In ODT, overshoots was showed in 22% of patients. (3) ETT showed type III or IV curves in 55.6% of patients. (4) OKP test decreased in 59% of patients. (5) Caloric test showed canal paresis in 85% of the patients. (6) Abnormal visual suppression test occurred in 60% of patients. (7) Abnormal ABR was found in 89% of patients. We also found that tumor larger than 2.5 cm presented a central type nystagmus (Bruns nystagmus) and involvement of the eye movement system. The electronystagmographic changes of the tumors of cerebellum (3 cases) and brain stem (4 cases) was discussed.
 ...
PMID:[Electronystagmographic changes in patients with posterior cranial fossa tumors]. 803 98

Chronic disability after stroke represents a major unmet neurologic need. ReNeuron's development of a human neural stem cell (hNSC) therapy for chronic disability after stroke is progressing through early clinical studies. A Phase I trial has recently been published, showing no safety concerns and some promising signs of efficacy. A single-arm Phase II multicenter trial in patients with stable upper-limb paresis has recently completed recruitment. The hNSCs administrated are from a manufactured, conditionally immortalized hNSC line (ReNeuron's CTX0E03 or CTX), generated with c-mycERTAM technology. This technology has enabled CTX to be manufactured at large scale under cGMP conditions, ensuring sufficient supply to meets the demands of research, clinical development, and, eventually, the market. CTX has key pro-angiogenic, pro-neurogenic, and immunomodulatory characteristics that are mechanistically important in functional recovery poststroke. This review covers the progress of CTX cell therapy from its laboratory origins to the clinic, concluding with a look into the late stage clinical future.
 ...
PMID:Human Neural Stem Cell Therapy for Chronic Ischemic Stroke: Charting Progress from Laboratory to Patients. 2844 71